ByHeart Secures $90M Series B Financing and Achieves All of its Clinical Trial Endpoints
ByHeart, a baby nutrition company, secured $90M in Series B funding, following a $70M Series A in April 2020, to launch its innovative infant formula after completing a significant clinical trial. The company aims to modernize baby nutrition with products based on advanced nutrition science and breast milk research, challenging the traditional infant formula market dominated by three companies. ByHeart's approach includes owning the entire manufacturing process and conducting comprehensive clinical trials, setting a new standard in the industry.
Reference News
ByHeart, a baby nutrition company, secured $90M in Series B funding, following a $70M Series A in April 2020, to launch its innovative infant formula after completing a significant clinical trial. The company aims to modernize baby nutrition with products based on advanced nutrition science and breast milk research, challenging the traditional infant formula market dominated by three companies. ByHeart's approach includes owning the entire manufacturing process and conducting comprehensive clinical trials, setting a new standard in the industry.